EC Number |
Application |
Reference |
---|
2.3.1.97 | analysis |
the automated assay can be used for proteomic studies to determine the myristoylation state of any protein |
657535 |
2.3.1.97 | drug development |
NMT is a putative drug target |
705604 |
2.3.1.97 | drug development |
the enzyme is a drug target |
703221 |
2.3.1.97 | drug development |
the enzyme is a potential target for development of therapeutic agents against visceral leishmaniasis |
-, 705181 |
2.3.1.97 | drug development |
the enzyme is a potential target for drug development |
-, 705181 |
2.3.1.97 | drug development |
the enzyme is a target for drug design in the treatment of epilepsy |
706573 |
2.3.1.97 | drug development |
the enzyme N-myristoyltransferase represents a promising drug target |
720195 |
2.3.1.97 | medicine |
both NMT1 and hnRNP A2/B1 may take part in the regulation of HIV-1 RNA expression through their mutual opposite effects on the viral RNA expression in HIV-1-producing cells |
735612 |
2.3.1.97 | medicine |
infection of HeLa cells with coxsackievirus B3 in the presence of NMT inhibitor DDD85646 decreases capsid protein VP0 acylation at least 100fold, resulting in a defect both early and late in virus morphogenesis, which diminishes the yield of viral progeny by about 90%. Virus particles still produced consist mainly of provirions containing RNA and uncleaved VP0 and, to a substantially lesser extent, of mature virions with cleaved VP0. Neither parechoviruses nor kobuviruses are affected by DDD85646. Individual knockout of the genes encoding the two human NMT isozymes in haploid HAP1 cells demonstrates the pivotal role for isoform NMT1, with little contribution by NMT2 |
758195 |
2.3.1.97 | medicine |
pharmacological inhibition of host cell N-myristoylation rapidly and completely prevents rhinoviral replication without inducing cytotoxicity. Inhibition of cotranslational myristoylation virus-encoded protein VP0 by inhibitor 1-(5-[3,4-difluoro-2-[2-(1,3,5-trimethyl-1H-pyrazol-4-yl)ethoxy]phenyl]-1-methyl-1H-indazol-3-yl)-N,N-dimethylmethanamine potently blocks a key step in viral capsid assembly, delivering low nanomolar antiviral activity against multiple rhinovirus strains, poliovirus and foot-and-mouth disease virus, and protection of cells against virus-induced killing, highlighting the potential of host myristoylation as a drug target in picornaviral infections |
757728 |